Latest Research And Development News

Cochlear Limited has reported a robust half-year performance with a 7% increase in underlying net profit and an 8% rise in interim dividends, driven by strong sales in cochlear and acoustic implants despite a decline in services revenue.

Archer Materials has successfully detected spin states in its carbon-based quantum material using a novel resonator design, marking a pivotal step toward functional qubit development for quantum computing.

Pro Medicus Limited delivered a robust half-year performance ending December 2024, with after-tax profits soaring 42.7% to $51.74 million and revenues climbing 31.1% to $97.2 million, driven by significant contract wins in North America and sustained growth in Australia.

Cycliq Group Limited reported an 18% revenue increase to $2.9 million for the half-year ending December 2024, driven by higher transaction values and a revamped marketing strategy, despite a modest net loss of $211,214.

Echo IQ has secured a $1.26 million refund under the Australian Government's R&D Tax Incentive, reinforcing its commitment to AI-driven solutions for structural heart disease detection.

IMDEX Limited reported a significant 84% increase in net profit for the half-year ended December 31, 2024, even as revenue declined by 10%. The company declared a steady interim dividend, underscoring confidence amid mixed financial signals.

Argenica Therapeutics reported a 16% reduction in half-year losses to $1.19 million, buoyed by a 29% increase in other income largely from R&D tax incentives, as it advances its neuroprotective drug development.

Cann Group Limited has negotiated an extension of its NAB loan maturity and deferred upcoming interest payments, providing crucial breathing room for its capital projects and working capital needs.

Reckon Limited posted a modest revenue increase to $54.1 million for FY2024, yet net profit declined by 25.7%, reflecting margin pressures despite operational gains. The company also announced a strategic acquisition aimed at bolstering future growth.

CSL Limited reported a solid half-year performance with 5% revenue growth and a 7% rise in net profit, driven by strong demand in its Behring and Vifor segments despite challenges in Seqirus. The company reaffirmed its full-year NPATA guidance of 10-13%, signaling confidence in its operational momentum.

CSL Limited reported a solid 5% revenue increase and 6% rise in net profit after tax for the half year ended December 2024, underpinned by robust performance in its plasma therapies business despite headwinds in its influenza vaccine segment.

Queste Communications Ltd reported a robust $4.2 million net cash increase in January 2025, driven primarily by positive operating cash flows and strategic investing activities. The company’s consolidated cash position benefits from its controlling stake in Orion Equities Limited.